Is a complete CGTX research report available?

No complete published report is available for Cognition Therapeutics, Inc. (CGTX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Cognition Therapeutics, Inc. (CGTX)

NASDAQ: CGTX · USD

$0.92

+0.01 (+1.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CGTX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	82M
Net income (ttm)	-19.6M
EPS (ttm)	-$0.25
Shares out	89.5M
Volume	259,321
Beta	1.75
Price target	$3.50	+282.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -19.6M
EPS (ttm): -$0.25
Market cap: 82M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CGTX indicators

Market & fundamental data

Available fields

187

Groups with data

Currency

USD

Showing 187 of 187 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001455365
Company name	Cognition Therapeutics, Inc.
Country	United States
Country code	US
Cusip	19243B102
Employees	14
Employees Change	-14%
Employees Change Percent	-50
Enterprise value	$51.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-10-08
Isin	US19243B1026
Last refreshed	2026-07-31
Market cap	$82M
Market cap category	Micro-Cap
Price	$0.92
Price currency	USD
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2836
Symbol	CGTX
Website	https://www.cogrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.88%
FCF yield	-24.7%
P/B ratio	2.74x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-19.6M
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Profit Per Employee	$-1.4M
ROA	-89.79
Roa5y	-71.37
ROCE	-142.4
ROE	-92.82
Roe5y	-86.63
ROIC	-123.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	36.71%
Cagr3y	-18.78%
EPS Growth Quarters	6
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$36.1M
Cash	$31.1M
Current Assets	$35.8M
Current Liabilities	$6.1M
Debt	$465,000
Debt Equity	$0.02
Equity	$29.9M
Interest Coverage	-3,295.5
Liabilities	$6.2M
Long Term Assets	$326,000
Long Term Liabilities	$176,000
Net Cash	$30.7M
Net Cash By Market Cap	$37.41
Net Cash Growth	94.17%
Net Debt Equity	$-1.03
Tangible Book Value	$29.9M
Tangible Book Value Per Share	$0.33
WACC	13.83

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.92
Net Working Capital	$-1.1M
Quick ratio	5.75
Working Capital	$29.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-70.27%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	36.68%
200-day SMA	1.28
3Y total return	-46.43%
50-day SMA	1.15
50-day SMA vs 200-day SMA	50under200
All Time High	13.8
All Time High Change	-93.36%
All Time High Date	2021-10-08
All Time Low	0.22
All Time Low Change	312.06%
All Time Low Date	2025-05-28
ATR	0.09
Beta	1.75
Beta1y	3.39
Beta2y	2.75
Ch YTD	-32.15
High	0.93
High52	3.83
High52 Date	2025-08-25
High52ch	-76.08%
Low	0.89
Low52	0.55
Low52 Date	2026-03-30
Low52ch	66.52%
Ma50ch	-20.42%
Premarket Change Percent	-1.23
Premarket Price	$0.89
Premarket Volume	5,835
Price vs 200-day SMA	-28.44%
RSI	39.04
RSI Monthly	42.19
RSI Weekly	40.73
Sharpe ratio	0.86x
Sortino ratio	1.4
Total Return	-70.27%
Tr YTD	-32.15
Tr1m	-15.96%
Tr1w	-4.6%
Tr3m	-22.37%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$3
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.06
Earnings Revenue Estimate	1,000,000x
Operating Income	$-42.8M
Price target	$3.5
Price Target Change	$282
Price Target Change Top	$228

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	81,826,417%
Float Percent	91.43%
Net Borrowing	-348,000
Shares Insiders	1.87%
Shares Institutions	18.8%
Shares Out	89,498,015
Shares Qo Q	0.66%
Shares Yo Y	70.27%
Short Float	11.83%
Short Ratio	3.82
Short Shares	10.81

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-22.1M
Adjusted OCF	-22,084,000
Average Volume	1,131,771x
Bv Per Share	0.33
Ch1m	-15.96
Ch1w	-4.6
Ch1y	36.68
Ch3m	-22.37
Ch3y	-46.43
Ch6m	-26.13
Change	1.65%
Change From Open	2.32
Close	0.9
Days Gap	-0.65
Depreciation Amortization	20,250
Dollar Volume	237,538
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-42.8M
EBITDA	$-42.6M
EPS	$-0.25
F Score	1
FCF	$-20.3M
FCF EV Yield	-39.47x
FCF Per Share	$-0.23
Financing CF	35,041,000
Fiscal Year End	December
Founded	2,007
Investing CF	9,000
Ipr	-92.37
Iprfo	-92.46
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	1.16
Ma150ch	-20.97%
Ma20	1
Ma20ch	-8.08%
Net CF	14,797,000
Next Earnings Date	2026-08-10
Open	0.9
Optionable	No
Position In Range	64.6
Post Close	0.92
Postmarket Change Percent	0.43
Postmarket Price	$0.92
Ppne	326,000
Pre Close	0.9
Price Date	2026-07-30
Ptbv Ratio	2.74
Relative Volume	0.23x
Share Based Comp	1,831,000
Tr6m	-26.13%
Us State	New York
Volume	259,321

Cognition Therapeutics, Inc. (CGTX)

Coverage state: Market snapshot only — no published research

Generate the first CGTX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CGTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CGTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CGTX

Frequently asked questions